AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Dyadic shares surge 19.34% premarket after CRISPR/Cas9 patent partnership with ERS Genomics.
ByAinvest
Tuesday, Dec 2, 2025 4:06 am ET1min read
Dyadic International Inc. surged 19.34% in premarket trading following two strategic developments: a licensing agreement for CRISPR/Cas9 technology from ERS Genomics and a partnership with Brig Bio to develop and commercialize biologics. The CRISPR deal enhances Dyadic’s genetic engineering capabilities, positioning it to improve bioproduction efficiency and scalability, while the Brig Bio collaboration secures funding for development milestones, validating its platform’s commercial potential. Both partnerships signal long-term growth opportunities in biotechnology, aligning with investor optimism despite mixed third-quarter earnings. The premarket rally reflects market anticipation of these strategic pivots, which could drive future revenue and industry relevance.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet